- Home
- PRSO vs REVB Comparison
PRSO vs REVB Comparison
Compare PRSO & REVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRSO
- REVB
- Stock Information
- Founded
- PRSO 2008
- REVB 2020
- Country
- PRSO United States
- REVB United States
- Employees
- PRSO N/A
- REVB N/A
- Industry
- PRSO Semiconductors
- REVB Biotechnology: Pharmaceutical Preparations
- Sector
- PRSO Technology
- REVB Health Care
- Exchange
- PRSO Nasdaq
- REVB Nasdaq
- Market Cap
- PRSO 4.5M
- REVB 3.8M
- IPO Year
- PRSO 2001
- REVB N/A
- Fundamental
- Price
- PRSO $0.85
- REVB $2.70
- Analyst Decision
- PRSO Strong Buy
- REVB
- Analyst Count
- PRSO 1
- REVB 0
- Target Price
- PRSO $3.00
- REVB N/A
- AVG Volume (30 Days)
- PRSO 124.1K
- REVB 164.5K
- Earning Date
- PRSO 08-11-2025
- REVB 08-08-2025
- Dividend Yield
- PRSO N/A
- REVB N/A
- EPS Growth
- PRSO N/A
- REVB N/A
- EPS
- PRSO N/A
- REVB N/A
- Revenue
- PRSO $13,608,000.00
- REVB N/A
- Revenue This Year
- PRSO $0.69
- REVB N/A
- Revenue Next Year
- PRSO $35.21
- REVB N/A
- P/E Ratio
- PRSO N/A
- REVB N/A
- Revenue Growth
- PRSO 1.80
- REVB N/A
- 52 Week Low
- PRSO $0.52
- REVB $2.11
- 52 Week High
- PRSO $2.34
- REVB $168.00
- Technical
- Relative Strength Index (RSI)
- PRSO 43.33
- REVB 51.87
- Support Level
- PRSO $0.80
- REVB $2.39
- Resistance Level
- PRSO $0.93
- REVB $2.70
- Average True Range (ATR)
- PRSO 0.05
- REVB 0.19
- MACD
- PRSO 0.01
- REVB 0.05
- Stochastic Oscillator
- PRSO 54.46
- REVB 76.61
About PRSO Peraso Inc.
Peraso Inc is a fabless semiconductor company focused on the development and sale of: i) millimeter wavelength wireless technology, or mmWave, semiconductor devices and antenna modules based on its proprietary semiconductor devices and ii) performance of non-recurring engineering, or NRE, services and licensing of intellectual property, or IP. The company's primary focus is the development of mmWave, which is generally described as the frequency band from 24 Gigahertz, or GHz, to 300 GHz. Geographically the company generates revenue from the United States, Hong Kong, Taiwan, and the Rest of the World.
About REVB Revelation Biosciences Inc.
Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).